Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide

Androgen deprivation therapy (ADT) is an important component of systemic therapy in advanced prostate cancer; however, resistance to ADT is inevitable. Three large studies demonstrated the efficacy of novel androgen receptor (AR)-targeted therapies in prolonging metastasis-free survival and time to...

Descripción completa

Detalles Bibliográficos
Autores principales: Gul, Anita, Garcia, Jorge A, Barata, Pedro C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682169/
https://www.ncbi.nlm.nih.gov/pubmed/31534371
http://dx.doi.org/10.2147/CMAR.S165706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682169/
https://www.ncbi.nlm.nih.gov/pubmed/31534371
http://dx.doi.org/10.2147/CMAR.S165706

Ejemplares similares